相似文献
1
Muscle matters in Kennedy's disease.
Neuron. 2014 Apr 16;82(2):251-3. doi: 10.1016/j.neuron.2014.04.005.
2
Distinct Etiological Roles for Myocytes and Motor Neurons in a Mouse Model of Kennedy's Disease/Spinobulbar Muscular Atrophy.
J Neurosci. 2015 Apr 22;35(16):6444-51. doi: 10.1523/JNEUROSCI.3599-14.2015.
3
Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy.
Neuron. 2014 Apr 16;82(2):295-307. doi: 10.1016/j.neuron.2014.03.001.
4
Androgen receptor mutation in Kennedy's disease.
Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1075-8. doi: 10.1098/rstb.1999.0461.
5
Spinobulbar muscular atrophy (Kennedy's disease): A rare diagnosis in the Greek population.
J Neurol Sci. 2015 Dec 15;359(1-2):450-1. doi: 10.1016/j.jns.2015.10.021. Epub 2015 Oct 21.
6
Kennedy's disease: pathogenesis and clinical approaches.
Intern Med J. 2004 May;34(5):279-86. doi: 10.1111/j.1444-0903.2004.00588.x.
7
A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.
Hum Mol Genet. 2016 May 15;25(10):1979-1989. doi: 10.1093/hmg/ddw073. Epub 2016 Mar 8.
8
Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion.
J Neurol Sci. 1996 Feb;135(2):149-57. doi: 10.1016/0022-510x(95)00284-9.
9
Human adipose-derived mesenchymal stem cells as a new model of spinal and bulbar muscular atrophy.
PLoS One. 2014 Nov 13;9(11):e112746. doi: 10.1371/journal.pone.0112746. eCollection 2014.
10
Identification of novel polyglutamine-expanded aggregation species in spinal and bulbar muscular atrophy.
Brain Res. 2015 Dec 2;1628(Pt B):254-264. doi: 10.1016/j.brainres.2015.09.033. Epub 2015 Oct 8.
引用本文的文献
1
AR cooperates with SMAD4 to maintain skeletal muscle homeostasis.
Acta Neuropathol. 2022 Jun;143(6):713-731. doi: 10.1007/s00401-022-02428-1. Epub 2022 May 6.
2
Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity.
Sci Adv. 2021 Aug 20;7(34). doi: 10.1126/sciadv.abi6896. Print 2021 Aug.
3
NMJ-Analyser identifies subtle early changes in mouse models of neuromuscular disease.
Sci Rep. 2021 Jun 10;11(1):12251. doi: 10.1038/s41598-021-91094-6.
4
A Crucial Role for the Protein Quality Control System in Motor Neuron Diseases.
Front Aging Neurosci. 2020 Jul 21;12:191. doi: 10.3389/fnagi.2020.00191. eCollection 2020.
5
The Role of Sex and Sex Hormones in Neurodegenerative Diseases.
Endocr Rev. 2020 Apr 1;41(2):273-319. doi: 10.1210/endrev/bnz005.
6
Biomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review.
Front Neurol. 2018 Oct 10;9:844. doi: 10.3389/fneur.2018.00844. eCollection 2018.
7
Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.
J Neurol. 2019 Mar;266(3):565-573. doi: 10.1007/s00415-018-8968-7. Epub 2018 Jul 13.
8
The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy.
J Neurol. 2018 May;265(5):1026-1036. doi: 10.1007/s00415-018-8790-2. Epub 2018 Feb 20.
9
Androgen Receptor Structure, Function and Biology: From Bench to Bedside.
Clin Biochem Rev. 2016 Feb;37(1):3-15.
10
Targeted Molecular Therapies for SBMA.
J Mol Neurosci. 2016 Mar;58(3):335-42. doi: 10.1007/s12031-015-0676-5. Epub 2015 Nov 17.
本文引用的文献
1
Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy.
Cell Rep. 2014 May 8;7(3):774-84. doi: 10.1016/j.celrep.2014.02.008. Epub 2014 Apr 16.
2
Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy.
Neuron. 2014 Apr 16;82(2):295-307. doi: 10.1016/j.neuron.2014.03.001.
3
Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.
Mol Med. 2012 Dec 6;18(1):1261-8. doi: 10.2119/molmed.2012.00271.
4
Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy.
J Neurosci. 2012 Jun 20;32(25):8703-15. doi: 10.1523/JNEUROSCI.0204-12.2012.
5
Developing treatment for spinal and bulbar muscular atrophy.
Prog Neurobiol. 2012 Dec;99(3):257-61. doi: 10.1016/j.pneurobio.2012.05.012. Epub 2012 Jun 2.
6
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
Nature. 2011 Oct 5;478(7367):123-6. doi: 10.1038/nature10485.
7
Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.
Lancet Neurol. 2011 Feb;10(2):140-7. doi: 10.1016/S1474-4422(10)70321-5. Epub 2011 Jan 6.
8
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet Neurol. 2010 Sep;9(9):875-84. doi: 10.1016/S1474-4422(10)70182-4. Epub 2010 Aug 4.
9
Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy.
Neuron. 2009 Aug 13;63(3):316-28. doi: 10.1016/j.neuron.2009.07.019.
10
Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease.
Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18259-64. doi: 10.1073/pnas.0705501104. Epub 2007 Nov 2.
Zotero 插件